胰升血糖素样肽鄄1及其受体与2型糖尿病的治疗  

Glucagon-like Peptide-1 and Its Receptors and Their Fuctions in The Treatment of Type 2 Diabetes Mellitus

作　　者：范益军[1] 欧阳克清[1] 王贵学[1] 胡应和[1] 

机构地区：[1]重庆大学生物工程学院生物力学与组织工程教育部重点实验室,重庆400044

出　　处：《生物化学与生物物理进展》2005年第5期393-396,共4页Progress In Biochemistry and Biophysics

摘　　要：胰岛素对治疗2型糖尿病有一定效果,但长期使用会引起低血糖反应;双胍类药物降糖疗效显著,但会引起消化道不良反应.因此,寻找一种安全有效的药物是2型糖尿病治疗的当务之急.胰升血糖素样肽-1作为一种胰岛素分泌促进剂和胰岛素增敏剂越来越受人们的关注,将它用于治疗糖尿病不会产生低血糖,对1型和2型糖尿病都有疗效.讨论胰升血糖素样肽-1及其受体的最新研究状况.Insulin is widely used as an effective therapeutic drug for the treatments of type I and type 2 diabetes mellitus. The side effect of insulin in type 2 diabetes is that it may cause hypoglycemia. Another common used prescription drug for type 2 diabetes is gliclazide. This drug is as effective as insulin, but it may cause the side effect in enteron. It is extremely important to develop a novel safe and effective therapeutic drug for type 2 diabetes. Recently, research from pharmaceutical companies and many institutions demonstrated that glucagon-like peptide-1 (GLP-1) is an excellent therapeutic target for type 2 diabetes. GLP-1 can promote the secretion of insulin and enhance its sensitivity. Further-more, treatment of type 2 diabetes patients with GLP-1 does not lead to hypoglycemia. More recent studies showed that GLP-1 is effective for both type 1 and type 2 diabetes mellitus. The latest research status of glucagon-like peptide-1 and its receptors is reviewed.

关 键 词：2型糖尿病 胰升血糖素样肽-1 胰升血糖素样肽-1受体 

分 类 号：R587.1[医药卫生—内分泌]